Clinical Rationale for a Routine Testing Schedule Using Donor-Derived Cell-Free DNA After Kidney Transplantation

Akshta Pai; Joshua T. Swan; David Wojciechowski; Yasir Qazi; Sham Dholakia; Grigoriy Shekhtman; Anas Abou-Ismail; Dhiren Kumar

doi:10.12659/AOT.932249

02 July 2021: Review Paper

Clinical Rationale for a Routine Testing Schedule Using Donor-Derived Cell-Free DNA After Kidney Transplantation

Akshta Pai ^1ADEF* , Joshua T. Swan ^23ADEF , David Wojciechowski ^4ADEF , Yasir Qazi ^5ADEF , Sham Dholakia ^6ADEF , Grigoriy Shekhtman ^6ADEF , Anas Abou-Ismail ^6ADEF , Dhiren Kumar ^7ADEF

DOI: 10.12659/AOT.932249

Ann Transplant 2021; 26:e932249

Authors information Article notes Copyright and License information

Background Immunosuppression in the First Year After Transplantation Rationale of dd-cfDNA Surveillance Time Points Quarterly Surveillance: Year 2 and Beyond Conclusions References

View HTML version

Figure 1 Graphic depicting the potential added value of donor-derived cell-free DNA (dd-cfDNA) surveillance for augmenting clinical decision making in posttransplant management. SCr – serum creatinine; DSA – donor-specific antibodies; PRA – panel reactive antibodies; IS – immunosuppressive therapy.

Back to the Article

Clinical Rationale for a Routine Testing Schedule Using Donor-Derived Cell-Free DNA After Kidney Transplantation

Your Privacy